When Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance merged, it was a marriage of complementary strengths for the already close partners. However, now under one umbrella as the Fred Hutchinson Cancer Center, or simply Fred Hutch as it is often called, it’s highlighting the newly unified research and clinical care programs with a new brand identity.
Amazon is partnering with the Fred Hutchinson Cancer Research Center on a Phase I trial for a cancer vaccine targeting metastatic melanoma and breast cancer.
WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic lymphocytic leukemia (“CLL”), have been selected for a poster presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (“ASTCT”) and Center for International Blood & Marrow Transplant Research (“CIBMTR”), taking place February 2 – 6, 2022 in Salt Lake City, Utah (“2022 Tandem Meetings”). MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Research Center (“Fred Hutch”).
Researchers uncovered an approved drug that may be able to combat COVID cytokine storms, but Takeda will not supply Iclusig for clinical trials.
Amid the company becoming Squelgene, Lynch hit the exit in the summer and went on to “pursue other healthcare opportunities.” A few months back, he landed at cancer biotech Kleo Pharmaceuticals as its chairman, but Lynch has now taken up a bigger role at the Fred Hutchinson Cancer Research Center.
Amid the company becoming Squelgene, Lynch hit the exit in the summer and went on to “pursue other healthcare opportunities.” A few months back, he landed at cancer biotech Kleo Pharmaceuticals as its chairman, but Lynch has now taken up a bigger role at the Fred Hutchinson Cancer Research Center.
Amid the company becoming Squelgene, Lynch hit the exit in the summer and went on to “pursue other healthcare opportunities.” A few months back, he landed at cancer biotech Kleo Pharmaceuticals as its chairman, but Lynch has now taken up a bigger role at the Fred Hutchinson Cancer Research Center.